EG 427 appoints Chief Medical Officer

October 30, 2022

EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions based on its unique non-replicative HSV-1 vector platform, announced today the appointment of Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer. Dr. Haag-Molkenteller is a board-certified urologist with more than 30 years of global experience in clinical development and medical affairs. She has tremendous experience with regulatory agencies across the full clinical development cycle, with both biologics and small molecules, in particular in the field of urology and neuro-urology.

 

Download the full Press Release


Recent posts

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.